Azitra, Inc.
AZTR Healthcare Biotechnology
Azitra, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $7,500.00, down 98.9% from fiscal 2023. In the quarter to June 2026, EPS grew 85.6% and free cash flow fell 19.6%, each against the same quarter a year earlier.
Follow AZTR
Azitra, Inc. (AZTR) EV/Sales
As of 14 October 2026, Azitra, Inc. (AZTR) trades at a EV/Sales of −9.3×. Over the past ten years it has ranged from −12.8× (June 2026) to 28.8× (June 2023); the current reading is higher than 8% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2024 | −5.0× | — |
| FY2023 | 8.0× | (72.30%) |
| FY2022 | 28.8× | 0.00% |
| FY2021 | 28.8× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2024 | 4.3× | (46.35%) |
| Dec 2023 | 8.0× | (62.75%) |
| Sep 2023 | 21.4× | 296.08% |
| Jun 2023 | 5.4× | (81.23%) |
| 4 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| AZTR Azitra, Inc. | −9.3× |
| DRMA Dermata Therapeutics, Inc. compare | n/m |
| LIMN Liminatus Pharma Inc. compare | n/m |
| NCNA NuCana PLC Sponsored ADR compare | n/m |
| ENLV Enlivex Ltd. compare | n/m |
| JUNS Jupiter Neurosciences, Inc. compare | n/m |
| OSRH OSR Health, Inc. compare | 6.2× |
| LNAI Lunai Bioworks Inc. compare | 18.7× |
| ADTX Aditxt, Inc. compare | 73.3× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)